AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04835714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441
Study NCT05076032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXO-001
Description: OXO-001 oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks approximately.
Study NCT05076032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral administration once daily in the early morning. The treatment duration will vary depending on the woman, but it will last between 10 to 14 weeks, approximately.
Study NCT05932589 — intervention group
Intervention type: OTHER
Intervention: EEG and Auditory and Visual Evoked Potentials (AEP and VEP)
Description: Through up to eight standardized sessions, participants will undergo AEP and VEP, as well as resting state EEG.
Study NCT05932589 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: Established clinical measures for RTT will be collected for RTT participants
Study NCT05278546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB2109
Description: ILB2109 tablets by mouth once per day at dosages prespecified by the protocol. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
Study NCT04756193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound
Description: Point of care ultrasound including echocardiography, lung ultrasound, vascular ultrasound, ECG, pulse oximetry, blood draw, spirometry
Study NCT05377554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein will be infused during the pre-operative period.
Study NCT05377554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative Visualization using White Light Reflectance (WLR) with Fluorescence (FL) Overlay
Description: Intra-operative real time nerve visualization will be undertaken using WLR with FL Overlay.
Study NCT05377554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-operative Visualization using White Light Reflectance (WLR)
Description: Intra-operative real time nerve visualization will be undertaken using WLR.
Study NCT06231823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extraction
Description: Simple / surgical dental extraction for necrotic. irreversible pulpitis, unrestorable, and first permanent molars with sever molar incisor hypomineralization.
Study NCT05087914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa (100mg/25mg):
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study NCT04979780 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Retrospective cohort analysis using US Optum De-Identified EHR data.
Study NCT04979780 — intervention group
Intervention type: DRUG
Intervention: Low molecular weight heparin (LMWH)
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. LMWH (dalteparin, enoxaparin, tinzaparin)
Study NCT05087914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study NCT04979780 — intervention group
Intervention type: DRUG
Intervention: Direct Oral Anticoagulants (DOAC)
Description: Retrospective cohort analysis using US Optum De-Identified EHR data. DOAC (apixaban, dabigatran, edoxaban, rivaroxaban).
Study NCT05087914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Participants will take 2 capsules (one containing naproxen, and the other containing either placebo or carbidopa/levodopa) 3 times per day (TID) for 5 days, the first dose is given right after the surgical procedure.
Study NCT04836221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support
Description: Community Health Workers will conduct weekly phone calls to monitor blood pressure or blood glucose, to check in on patient need for social, practical or emotional supports, and to encourage healthy lifestyle modification.~Participants will also have access to a mobile app to support chronic disease management (Either diabetes or hypertension).
Study NCT05404425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visioconference: live visual injury evaluation
Description: For patients randomized in the intervention group, a live visual evaluation of the injury is performed by the Emergency Medical Call Center physician using a dedicated, secure smartphone app
Study NCT05404425 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: For patients randomized in the control group, the evaluation is performed by the Emergency Medical Call Center physician only by pone call
Study NCT06058442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NORTASE®
Description: 10-15 capsules of NORTASE® per day - over 6 months
Study NCT04836858 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMK389
Description: Active
Study NCT04836858 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT06437236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: Group A will receive ondansetron 4mg diluted in normal saline,The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block
Study NCT06437236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron
Description: Group B will receive granisetron 1mg diluted in normal saline.The total volume of the solution infused will kept at 10 mL.~After preloading, patients in the respective group will receive the infusion of the study drug over 1 minute just 5 minutes before performing the subarachnoid block
Study NCT04005534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard group
Description: Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Study NCT04005534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive group
Description: Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
Study NCT05292534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid amplification
Description: Hearing aid will be fit to prescribed participant hearing loss.
Study NCT05292534 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hearing aid amplification with an added sound
Description: Hearing aid will be fit to prescribed participant hearing loss and an added sound will be activated.
Study NCT06424847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention (physical activity and diet)
Description: The physical activity intervention will be based on validated behavior change theories aimed at the initiation and long-term maintenance of physical activity.~Participants will be referred to specialists in Adapted Physical Activity for a 6-month program. Exercise sessions will include aerobic exercise and muscle strengthening exercises. Participants will participate in one supervised sessions per week. They will receive instructions for exercising on their own on the other days in order to reach physical activity guidelines. They will also receive instructions and tips to limit sedentary behavior and increase their physical activity throughout the day.~Participants will benefit from an initial consultation with a dietitian and 4 follow-up visits. The follow-up visits will be either group-based or individual, based on participants choice and availabilities. Dietary recommendations will be based on public health guidelines in France aimed at eating a healthy, balanced diet.
Study NCT06424847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle (physical activity and diet) and Sleep intervention
Description: Participants will benefit from the physical activity and diet intervention detailed above and the following sleep intervention. Participants will fill out an online sleep diagnostic tool includes validated sleep questionnaires (Pittsburgh Sleep Quality Index, Epworth sleepiness scale, Insomnia Severity Index, Berlin questionnaire, Horne and Ostberg questionnaire).~Participants will also log their sleep habits in a 14-day sleep diary. Based on the sleep specialists' review of the results of the questionnaires, sleep diary and analysis of sleep-wake patterns, participants who require further exploration will be referred to a sleep specialist for a consultation and if necessary the appropriate treatment for their sleep disorder.~All participants in this group will benefit from an individualized sleep hygiene intervention. They will benefit from a baseline interview and 3 follow-up visits.
Study NCT06424847 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health education intervention
Description: Participants randomized to the control group will benefit from a health education intervention in order to limit deception bias.
Study NCT05177757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga exercise program will be conducted at the Marquette campus and will consist of one session per week for 12 weeks. The duration of each session will be approximately one hour. The program the investigators will use is the Mindful Resilience for Trauma Recovery Program (https://www.veteransyogaproject.org/), an evidence-informed practice adapted for veterans with PTSD based on clinical and neuroscientific knowledge. This program is a 12-week protocol developed by a licensed clinical psychologist and is publicly available. All yoga sessions will be standardized based on the resilience program guidelines.
Study NCT06058442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10-15 capsules of placebo per day - over 6 months
Study NCT06335797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Senna Tab
Description: Senna 8.6mg two tablets per day post operative day 1 and and if needed, then continue on the same dose regiment until post operative day 5.
Study NCT06335797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dulcolax Suppositories
Description: Dulcolax 1 suppository to be placed rectally on the evening of post operative day 1 and if needed, then continue using the same dose regiment until the post operative day 5.
Study NCT06532812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Tumor Infiltrating Lymphocytes (TIL) IV
Study NCT06532812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study NCT06532812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study NCT06532812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 will be started as a bolus administration every eight hours, for a maximum of eight doses.
Study NCT06532812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT05320835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV, HCV and overdose prevention
Description: HIV, HCV and overdose prevention
Study NCT05320835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV, HCV and overdose prevention
Description: HIV, HCV and overdose prevention
Study NCT06138509 — intervention group
Intervention type: OTHER
Intervention: Dosage of serotonin and metabolites
Description: The dosages of serotonin and its metabolites will be performed by the INSERM U1016 unit at Cochin Institute.
Study NCT06138509 — intervention group
Intervention type: OTHER
Intervention: Blood parameters
Description: The characterization of blood parameters : complete blood count (CBC), reticulocytes, C-reactive protein (CRP), iron studies (ferritin, serum iron, transferrin and transferrin saturation), hemoglobin electrophoresis, erythropoietin, will be added using standard methods at the Necker hematology laboratory if not carried out as part of the routine care.
Study NCT06355258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Troxerutin
Description: Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study NCT06355258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study NCT06355258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + low molecular weight heparin
Description: 2000 IU LMWH once a day + Oral placebo tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study NCT06355258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troxerutin + low molecular weight heparin
Description: 2000 IU LMWH once a day + Oral troxerutin tablets, with a dosage of 3 tablets (60 mg/tablet) orally, twice daily
Study NCT06253637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab plus chemotherapy according to the national treatment program
Description: Daratumumab is a human IgG1қ monoclonal antibody that binds with high affinity to a unique epitope on CD38, a transmembrane glycoprotein which is expressed in several hematological malignancies including multiple myeloma (MM) and ALL. Daratumumab induces lysis of CD38-expressing tumor cells by several mechanisms. Intravenous daratumumab has been approved first as a single agent and then in combinations in the MM setting and in AL amyloidosis.~The activity of daratumumab in ALL is being explored in the DELPHINUS trial, in which the drug was combined with chemotherapy in pediatric and young adult patients with relapsed/refractory T-cell ALL or lymphoblastic lymphoma (LL).~In the present trial, daratumumab will be administered to adult Very high risk T-lineage ALL weekly in induction and early consolidation (C1-C2), and the first day of each of the following intensive cycles up to C8.
Study NCT05184569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verdiperstat
Description: Oral, extended release (ER) tablet
Study NCT05184569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verdiperstat
Description: Oral, extended release (ER) tablet
Study NCT05987007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acoustic slow-wave activity enhancement
Description: The acoustic enhancement of slow-wave activity will be conducted using the Dreem2 headband. This device utilizes five dry-EEG electrodes (O1, O2, FpZ, F7, and F8), a 3D accelerometer, and a pulse oximeter to detect slow-wave activity and generates acoustic stimulation of slow-waves to augment slow-wave sleep.
Study NCT05987007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia
Description: Cognitive behavioral therapy for insomnia (CBTI) is a well-established first-line or complimentary treatment for insomnia which consists of cognitive and behavioral modifications, including addressing maladaptive sleep-related behaviors, controlling sleep environment, and limiting time spent in bed.
Study NCT06575088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard tourniquet pressure (250 mmHg)
Description: The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
Study NCT06575088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Limb occlusion pressure
Description: The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
Study NCT06575088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Pad
Description: The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
Study NCT06575088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic stockinette
Description: The effectiveness of the protective padding material placed on the skin with a pneumatic tourniquet cuff and the pneumatic tourniquet pressure determination methods were compared.
Study NCT05593198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Khoury technique
Description: the bone block will be used following the principles of the Khoury technique to augment the bone volume.
Study NCT05593198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided bone regeneration
Description: the membrane and the bone granules will be used to perform the guided bone regeneration technique.
Study NCT05889806 — intervention group
Intervention type: OTHER
Intervention: Observational Study Only. NO Intervention.
Description: Observational Study Only. NO Intervention.
Study NCT03166371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal Glutathione (GSH)
Description: Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
Study NCT03166371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
Study NCT04983758 — intervention group
Intervention type: OTHER
Intervention: Oral Rehabilitation with dental implants
Description: Patients have been treated with oral dental implants supporting fixed dental prostheses
Study NCT06003465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY3437943
Description: Administered SC
Study NCT06003465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC
Study NCT06003465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test
Description: Used to administer LY3437943 SC
Study NCT06003465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Used to administer LY3437943 SC
Study NCT05193344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital care solution for patients with Heart Failure
Description: A digital solution that provides remote symptom monitoring and support of lifestyle-changes by gamification, altruistic rewards, and engaging content with relevant tasks or missions to be completed.
Study NCT05193344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care for patients with Heart Failure
Description: The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
Study NCT05193344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care for patients with Heart Failure
Description: The best medical therapy including start or optimization of secondary preventive pharmacotherapy, and advise on modifiable risk factors. The participants in the control arm will also receive an information leaflet about relevant lifestyle modifications for HF.
Study NCT04797741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IDEA3 Intervention
Description: Delivery of IDEA3 intervention, a 12-hour online sexual assault resistance intervention for college women.
Study NCT06163482 — intervention group
Intervention type: OTHER
Intervention: Mixed meal
Description: Each individual will ingest 5 mL/kg of Boost energy drink.
Study NCT06403579 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: virtula reality goggles
Description: no intervention
Study NCT06403579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtula reality goggles
Description: no intervention
Study NCT04951674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fiber diet
Description: 30 grams of fiber per day
Study NCT04951674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: No diet education and change in diet
Study NCT05122078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. Investigators will not monitor ANI in this group.
Study NCT05565807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6129
Description: Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor.